OTCMKTS:TLOG

TetraLogic Pharmaceuticals Stock Forecast, Price & News

$0.04
-0.01 (-20.83 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04▼
$0.05
50-Day Range
$0.04
MA: $0.05▼
$0.06
52-Week Range
$0.01
Now: $0.04▼
$0.06
Volume16,485 shs
Average Volume34,349 shs
Market Capitalization$941,260.00
P/E RatioN/A
Dividend YieldN/A
Beta1.38
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
TetraLogic Pharmaceuticals logo

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TLOG
Previous SymbolNASDAQ:TLOG
CUSIPN/A
CIK1361248
Webwww.tetralogicpharma.com
Phone610-889-9900
Employees29
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares24,770,000
Market Cap$941,260.00
Next Earnings DateN/A
OptionableNot Optionable

Headlines

TetraLogic Pharmaceuticals Co. (OTCMKTS:TLOG) Sees Large Drop in Short Interest
March 30, 2021 |  americanbankingnews.com
TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Shares Pass Below 50-Day Moving Average of $0.05
March 24, 2021 |  americanbankingnews.com
TetraLogic Pharmaceuticals Corp
October 30, 2019 |  markets.ft.com
See More Headlines

MarketRank™

Overall MarketRank™

0.48 out of 5 stars

Medical Sector

1637th out of 2,019 stocks

Pharmaceutical Preparations Industry

682nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.04
-0.01 (-20.83 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TLOG News and Ratings via Email

Sign-up to receive the latest news and ratings for TLOG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Frequently Asked Questions

What stocks does MarketBeat like better than TetraLogic Pharmaceuticals?

Wall Street analysts have given TetraLogic Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TetraLogic Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TetraLogic Pharmaceuticals?

TetraLogic Pharmaceuticals saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 700 shares, a drop of 30.0% from the February 28th total of 1,000 shares. Based on an average daily trading volume, of 28,100 shares, the days-to-cover ratio is currently 0.0 days.
View TetraLogic Pharmaceuticals' Short Interest.

How has TetraLogic Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

TetraLogic Pharmaceuticals' stock was trading at $0.0270 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TLOG shares have increased by 40.7% and is now trading at $0.0380.
View which stocks have been most impacted by COVID-19.

Who are TetraLogic Pharmaceuticals' key executives?

TetraLogic Pharmaceuticals' management team includes the following people:
  • Dr. Yigong Shi, Co-Founder (Age 52)
  • Sarah E. Frew, Director of Bus. & Commercial Devel.

Who are some of TetraLogic Pharmaceuticals' key competitors?

Some companies that are related to TetraLogic Pharmaceuticals include Akorn (AKRXQ), VG Life Sciences (VGLS), Immune Pharmaceuticals (IMNPQ), Innovus Pharmaceuticals (INNVD), RespireRx Pharmaceuticals (RSPI), Inspyr Therapeutics (NSPX), Boston Therapeutics (BTHE), ImmunoCellular Therapeutics (IMUCD), VIVUS (VVUSQ), Capstone Therapeutics (CAPS), W World (WWHC), ImmunoCellular Therapeutics (IMUC), Earth Science Tech (ETST), Cardax (CDXI) and Aoxing Pharmaceutical (AOXG).
View all of TLOG's competitors.

What other stocks do shareholders of TetraLogic Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TetraLogic Pharmaceuticals investors own include Trevena (TRVN), Vaxart (VXRT), Arrowhead Pharmaceuticals (ARWR), (CELG), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Gilead Sciences (GILD), GoPro (GPRO), OHR Pharmaceutical (OHRP) and Achaogen (AKAO).

What is TetraLogic Pharmaceuticals' stock symbol?

TetraLogic Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TLOG."

How do I buy shares of TetraLogic Pharmaceuticals?

Shares of TLOG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TetraLogic Pharmaceuticals' stock price today?

One share of TLOG stock can currently be purchased for approximately $0.04.

How much money does TetraLogic Pharmaceuticals make?

TetraLogic Pharmaceuticals has a market capitalization of $941,260.00.

How many employees does TetraLogic Pharmaceuticals have?

TetraLogic Pharmaceuticals employs 29 workers across the globe.

What is TetraLogic Pharmaceuticals' official website?

The official website for TetraLogic Pharmaceuticals is www.tetralogicpharma.com.

Where are TetraLogic Pharmaceuticals' headquarters?

TetraLogic Pharmaceuticals is headquartered at 343 PHOENIXVILLE PIKE, MALVERN PA, 19355.

How can I contact TetraLogic Pharmaceuticals?

TetraLogic Pharmaceuticals' mailing address is 343 PHOENIXVILLE PIKE, MALVERN PA, 19355. The biopharmaceutical company can be reached via phone at 610-889-9900 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.